Tomas Philipson’s latest Forbes.com Op-Ed examines how international linkages between health care economies will affect how long you and your kids will live.
Tomas Philipson’s latest Forbes.com Op-Ed examines end of life care, and why health care is so valuable in the face of death.
Precision’s Tomas Philipson’s latest Forbes.com Op-Ed examines California’s recently enacted vaccination mandate, and the application of economic epidemiology.
Precision’s Dana Goldman and Senior Research Economist Karen Van Nuys, along with co-authors Victor J Dzau, Geoffrey S Ginsburg and David Agus, address new developments in personalized medicine.
Precision’s Tomas Philipson in his regular column in Forbes.com, talks about the precision medicine initiative as a more useful approach towards appropriate adherence behavior.
In Health Affairs, PHE’s Goldman and Lakdawalla suggest it’s time for value-based payment in oncology.
This real-world study measures the impact of a field force on market access when provided with physician-specific access opportunities and corresponding, personalized pull-through messages.
Precision offers an in-person, executive briefing series on critical issues affecting value propositions and market access. Insights to Access is available to select groups. Contact us for details. Insights to Access is an interactive, dynamic series of presentations featuring former payers who are now on the Precision Payer Strategy Team. They share knowledge and tactics regarding the latest payer trends, legislation, and market developments. These presentations foster a productive discussion that will help prepare your team to succeed as they face the most pressing issues in payer marketing today.
As healthcare spending continues to rise, payers and providers struggle to accurately measure value to patients, and with health systems all over the world shifting towards paying for value, not just volume, these efforts have never been more important. This research brief shares novel, groundbreaking studies that have helped define the value of new oncology drugs, and recommends new criteria for framing value in cancer care.
The recent entry of biosimilar anti-TNFs into the European markets has attracted considerable attention—much of it centered on competitive discounting. Yet proprietary research with key payers and clinicians from 9 European countries shows that customer decisions are largely not based on price. Discover the initiatives that can incentivize these influential decision-makers and when to most effectively leverage each in the decision-making chain.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
